ADF Awards

The ADF announces various prizes to reward scientists / researchers from the field of dermatological research. In addition to the Paul Langerhans Award for established researchers and the Egon Macher Award for young investigators outstanding works in the field of allergy research (ADF / ECARF Award of European Allergy Research) and oncology (Dermato Oncology Junior Scientist Award) will be honored on the ADF Annual Meetings.

In addition, the best posters will be awarded with a poster prize.

For the complete tender texts and the detailed allocation policies please click on the highlighted link.

Please note:
For poster prices, the ADF / ECARF Award for European Allergy Research, the Dermato Oncology Junior Scientist Awards and for the Translational Research Award, a separate application is not necessary. For these prices all abstracts submitted before the deadline will be evaluated.
Submissions for the Paul Langerhans Award and the Egon Macher Award should be made in all cases exclusively in electronic form as one PDF file to the ADF office.
Submission deadline: November 01.


Translational Research Award

Since 2006, the ADF has offered prizes in the field of translational research. The prizes were supported by the Dermatologikum Foundation from 2006-2014 and by Novartis Pharma GmbH from 2018-2021. 2023 this prize is supported bey Biogen GmbH.

These prizes will be awarded to researchers in the field of Dermatology who are attempting to transfer insights gained in experimental basic research into clinical applications. Junior scientists who present outstanding and innovative work in this field are preferably considered.

In 2024 awarded are 3 x 2.500,- EUR.

An independent scientific advisory board consisting of former ADF board members, clinic directors and leader of specific centers within dermatological clinics will select and nominate the awardees.

The Translational Research prizes will be awarded at the ADF Annual Meeting to researchers or clinician scientists (first or senior authors) who performed outstanding work in the field of Translational Research. The Translational Research prizes will cover different focus areas of dermatological research.

The prizes, which are awarded in different disciplines of dermatological research, will be awarded to first / senior authors during the ADF anniversary, which will carry out outstanding work in this field. Each application for the Translational Research Prize is reviewed by a number of members of the Board of Trustees, with the appraisers assigned to the individual applications in the batch process (to the exclusion of a possible bias). Subsequently, each reviewer evaluates the assignments assigned to him using a standardized point system according to the innovation and originality of the submitted work, their relevance and their possible potential for translation into clinical application. The work with the highest score in each category is awarded, whereby the division of the prizes is possible for the same number of points.

All contributions to clinical translation research that were submitted as an abstract on time to the ADF Annual Meeting will be considered.


  • PD Dr. med. Manfred Kneilling (Chair)
  • Prof. Dr. med. Patrick Brunner
  • Prof. Dr. med. Claudia Günther
  • Dr. med. Dr. s.c. nat. Barbara Meier-Schiesser
  • PD Dr. med. Oana-Diana Persa
  • PD Dr. med. Christian Posch
  • PD Dr. rer. nat. Verena Raker
  • Dr. med. Artem Vorobyev


Past awardees of the Translational Research Award

Shruti Chopra, Hanover
P053: The antimicrobial peptide RNase 7 induces the expression and secretion of the pro-inflammatory cytokine IL-6 by keratinocytes

Paula Meisel, Vienna
P189: Overexpression of DIRAS1 in mouse skin reduces tumorigenesis during multi-stage chemical carcinogenesis

Beatrice Balciunaite, Tuebingen
P217: Cutaneous squamous cell carcinoma patients harbour keratin 14 reactive T cells

Luisa Bopp, Cologne
P080: Imiquimod perturbs amino acid metabolism in human CD8+ T cells

Menatullah Mubarak, Munich
P020: The transcription factor CEBPB drives lichenoid skin inflammation by mediating apoptosis, IFN-? signaling and favoring the secretion of type 1-related inflammatory factors

Bastian Kruse, Magdeburg
P107: Adoptively transferred CD4+ T cells control established melanomas through indirect antigen-specific activation in the tumour microenvironment

Barbara Schwertner, Regensburg
P050: Nectin-1 determines the susceptibility of malignant melanoma to oncolytic herpes simplex virus in vitro and in vivo

Marta Torregrossa, Leipzig
P070: Local accumulation of iron in the skin affects crosstalk and phenotypes of immune and tissue cells

Sabrina Patzelt, Lübeck
P129: PDE4 inhibition improves clinical lesions in a novel immunization-induced mouse model of mucous membrane pemphigoid

Hanna Bonnekoh, Berlin
P041: Tocilizumab treatment in patients with Schnitzler syndrome: an open-label proof-of-concept study

Susanne Kimeswenger, Linz
P063: Artificial neural networks and pathologists recognize basal cell carcinomas based on different histological patterns

Frederic Valentin, Muenster
P089: Development of a Pathogenesis-Based Therapy for Peeling Skin Syndrome (PSS type 1)

Peter Seiringer, Munich
P098: Immunological patterns and therapeutic consequences of chronic inflammatory skin diseases

Akiko Arakawa, Munich
P137: Autoantigen generation of the HLA-C*06:02-mediated autoimmune response against melanocytes in psoriasis is ERAP1-dependent

Saptaswa Dey, Graz
P205: STAT5 is a therapeutically targetable vulnerability in leukemic cutaneous T-cell lymphoma

No Award

F. Meraz-Torres, Tübingen
P040: Disulfiram efficiently induces cell death in BRAF Wild-Type melanoma cells through a massive induction of reactive oxygen species

Anja Saalbach, Leipzig
P068: High fat diet exacerbates skin inflammation independent of obesity: Saturated fatty acids as key players

N. Zimmermann, Dresden
P055: Clinical response to JAK inhibition in patients with familial chilblain lupus and TREX1 mutation

Magda Babina, Berlin
P 016: Double-edged role of IL-33 in human skin mast cells: reduced degranulation, strengthened proliferation and heightened histamine synthesis through p38 activation

Sabrina Tofern, Lübeck
P130: Effect of phosphodiesterase-4 inhibition on skin and mucosal lesions in experimental anti-laminin 332 mucous membrane pemphigoid

Luisa Senra, Genf
P046: IL-17E (IL-25) enhances innate immune responses during murine skin inflammation

Farzan Solimani, Marburg
Therapeutic inhibition of IL-17 leads to clinical remission of lichen planus

E. Zanuttigh, München
The secretome of skin cancer cells influences the transcriptome of keratinocytes

Lenche Chakievska, Lübeck
Rationale for anti-IL-17A treatment in bullous pemphigoid

Henning Wiegmann, Münster
LEKTI is substrate of Transglutaminase-1: implication for a therapeutic topical replacement strategy for Netherton Syndrome

Maria Schneeweiß, Münster
Topical treatment with a novel kappa-opioid receptor agonist ameliorates atopic dermatitis

Tobias Sinnberg, Tübingen
Inhibition of melanoma cell derived prostaglandin E2 amplifies T- cell receptor signaling and shows clinical efficacy in combination with anti-PD1 therapy

A. Stegemann, Münster
Beta-endorphin - an emerging antifibrotic neuropeptide

N. Wagner, Heidelberg
RAGE ligands S100A8/A9 and HMGB1 as prognostic markers in melanoma

J. Stehn, Sydney
Developing chemotherapeutics which selectively disable the actin cytoskeleton of tumor cells

Misa Hirose, Lübeck
Enzymatic autoantibody glycan hydrolysis alleviates autoimmunity against type VII collagen

Katja Bieber, Lübeck
Modulation of experimental epidermolysis bullosa acquisita towards an improved phenotype by initiating the production of non-pathogenic autoantibodies

J. S. Kern, Freiburg
Cell therapy restores skin function in an immunocompetent mouse model for dystrophic epidermolysis bullosa

Robert Sabat, Berlin
Interleukin(IL)-22, a T-cell mediator, induces in keratinocytes IL-20, a tissue cell mediator: a novel cascade with major relevance for the pathogenesis of psoriasis The epidermal alterations in psoriasis are mediated by IL-22, but not by other T-cell mediators including IL-17 or IFN-, and are amplified by TNF-alpha.

Thomas Volz, Tübingen
Induction of IL-10 producing suppressor T cells by non-pathogenic gram-negative bacteria clears atopic dermatitis

E. Gaffal, Bonn
Contact hypersensitivity is significantly increased in cannabinoid receptorknockout mice: Evidence for the involvement of the endogenous cannabinoidsystem in the regulation of cutaneous immune responses.

S. Meyer, Regensburg
High-throughput tissue microarray analysis of MTAP expression inmelanocytic skin tumors.